Compare Stocks: LIMN, ALLR, NCEL, and CMMB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLR Allarity Therapeutics	$1.16 +4.1%	$1.29	$0.77 ▼ $1.84	$17.66M	0.56	94,163 shs	53,514 shs
CMMB Chemomab Therapeutics	$2.65 +7.3%	$2.03	$1.35 ▼ $3.58	$17.90M	0.76	116,515 shs	115,108 shs
LIMN Liminatus Pharma	$3.33 -5.1%	$5.09	$3.29 ▼ $141.50	$4.71M	5.3	45,751 shs	15,301 shs
NCEL NLS Pharmaceutics	$3.39 +2.1%	$3.50	$1.83 ▼ $24.60	$19.18M	0.94	7,806 shs	4,644 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLR Allarity Therapeutics	+4.05%	-8.48%	-13.81%	-19.23%	-24.01%
CMMB Chemomab Therapeutics	+7.29%	-1.49%	+38.02%	+65.32%	-5.36%
LIMN Liminatus Pharma	-5.13%	-4.31%	-52.90%	-44.13%	-96.28%
NCEL NLS Pharmaceutics	+2.11%	+4.31%	+3.99%	+2.42%	-84.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLR Allarity Therapeutics	$1.16 +4.1%	$1.29	$0.77 ▼ $1.84	$17.66M	0.56	94,163 shs	53,514 shs
CMMB Chemomab Therapeutics	$2.65 +7.3%	$2.03	$1.35 ▼ $3.58	$17.90M	0.76	116,515 shs	115,108 shs
LIMN Liminatus Pharma	$3.33 -5.1%	$5.09	$3.29 ▼ $141.50	$4.71M	5.3	45,751 shs	15,301 shs
NCEL NLS Pharmaceutics	$3.39 +2.1%	$3.50	$1.83 ▼ $24.60	$19.18M	0.94	7,806 shs	4,644 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLR Allarity Therapeutics	+4.05%	-8.48%	-13.81%	-19.23%	-24.01%
CMMB Chemomab Therapeutics	+7.29%	-1.49%	+38.02%	+65.32%	-5.36%
LIMN Liminatus Pharma	-5.13%	-4.31%	-52.90%	-44.13%	-96.28%
NCEL NLS Pharmaceutics	+2.11%	+4.31%	+3.99%	+2.42%	-84.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLR Allarity Therapeutics	2.00	Hold	$10.25	787.45% Upside
CMMB Chemomab Therapeutics	1.50	Reduce	N/A	N/A
LIMN Liminatus Pharma	1.00	Sell	N/A	N/A
NCEL NLS Pharmaceutics	2.00	Hold	$23.00	578.47% Upside

Current Analyst Ratings Breakdown

Latest LIMN, ALLR, NCEL, and CMMB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	LIMN Liminatus Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/20/2026	LIMN Liminatus Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/5/2026	CMMB Chemomab Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	ALLR Allarity Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	NCEL NLS Pharmaceutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/13/2026	NCEL NLS Pharmaceutics	Laidlaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$23.00
6/29/2026	NCEL NLS Pharmaceutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E)
6/24/2026	LIMN Liminatus Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLR Allarity Therapeutics	$320K	57.43	N/A	N/A	$0.61 per share	1.89
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$2.00 per share	N/A
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	($18.13) per share	N/A
NCEL NLS Pharmaceutics	N/A	N/A	N/A	N/A	$1.59 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLR Allarity Therapeutics	-$11.23M	-$0.78	N/A	N/A	N/A	N/A	-152.77%	-46.50%	11/13/2026 (Estimated)
CMMB Chemomab Therapeutics	-$8.99M	-$2.13	N/A	N/A	N/A	N/A	-92.14%	-82.05%	11/6/2026 (Estimated)
LIMN Liminatus Pharma	-$10.21M	-$23.50	N/A	N/A	N/A	N/A	N/A	-256.58%	N/A
NCEL NLS Pharmaceutics	-$8.30M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest LIMN, ALLR, NCEL, and CMMB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2026	Q2 2026	CMMB Chemomab Therapeutics	-$0.15	-$0.27	-$0.12	-$0.24	N/A	N/A
8/14/2026	Q2 2026	ALLR Allarity Therapeutics	-$0.25	-$0.21	+$0.04	-$0.21	N/A	N/A
8/14/2026	Q2 2026	LIMN Liminatus Pharma	N/A	-$1.50	N/A	-$0.03	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	N/A
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	N/A
NCEL NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLR Allarity Therapeutics	N/A	1.11	1.11
CMMB Chemomab Therapeutics	N/A	6.41	6.41
LIMN Liminatus Pharma	N/A	1.12	1.12
NCEL NLS Pharmaceutics	N/A	0.76	0.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLR Allarity Therapeutics	11.53%
CMMB Chemomab Therapeutics	46.05%
LIMN Liminatus Pharma	N/A
NCEL NLS Pharmaceutics	N/A

Insider Ownership

Company	Insider Ownership
ALLR Allarity Therapeutics	0.16%
CMMB Chemomab Therapeutics	11.91%
LIMN Liminatus Pharma	19.40%
NCEL NLS Pharmaceutics	16.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLR Allarity Therapeutics	10	15.91 million	15.89 million	Not Optionable
CMMB Chemomab Therapeutics	20	7.25 million	6.38 million	Not Optionable
LIMN Liminatus Pharma	N/A	1.34 million	1.08 million	N/A
NCEL NLS Pharmaceutics	6	5.78 million	4.83 million	Not Optionable

LIMN, ALLR, NCEL, and CMMB Headlines

Recent News About These Companies

Der aktuelle Kurs der NewcelX AG Aktie beträgt 3,380.

August 27, 2026 | de.investing.com

NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing

July 31, 2026 | globenewswire.com

NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board

July 8, 2026 | globenewswire.com

NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes

July 1, 2026 | globenewswire.com

NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform

June 15, 2026 | globenewswire.com

NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes

May 27, 2026 | globenewswire.com

NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026

April 30, 2026 | globenewswire.com

Michel Revel Purchases 54,545 Shares of NLS Pharmaceutics (NASDAQ:NCEL) Stock

April 30, 2026 | insidertrades.com

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference

April 20, 2026 | globenewswire.com

NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing

April 1, 2026 | globenewswire.com

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

March 9, 2026 | prnewswire.com

NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy

February 12, 2026 | prnewswire.com

NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences

January 29, 2026 | prnewswire.com

NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression

January 12, 2026 | prnewswire.com

NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board

January 5, 2026 | prnewswire.com

NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China

December 11, 2025 | prnewswire.com

NewCelX Appoints EY as New Auditor Following Merger

November 20, 2025 | tipranks.com

NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute

November 17, 2025 | prnewswire.com

NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board

November 6, 2025 | prnewswire.com

NewcelX Ltd.

November 5, 2025 | cnn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LIMN, ALLR, NCEL, and CMMB Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

$1.16 +0.05 (+4.05%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$1.21 +0.06 (+4.85%)

As of 08:30 AM Eastern

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Chemomab Therapeutics NASDAQ:CMMB

$2.65 +0.18 (+7.29%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$2.65 0.00 (0.00%)

As of 08:35 AM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Liminatus Pharma NASDAQ:LIMN

$3.33 -0.18 (-5.13%)

Closing price 09/16/2026 03:59 PM Eastern

Extended Trading

$3.48 +0.15 (+4.35%)

As of 08:13 AM Eastern

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

NLS Pharmaceutics NASDAQ:NCEL

$3.39 +0.07 (+2.11%)

As of 09/16/2026 03:59 PM Eastern

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LIMN, ALLR, NCEL, and CMMB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LIMN, ALLR, NCEL, and CMMB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LIMN, ALLR, NCEL, and CMMB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LIMN, ALLR, NCEL, and CMMB Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

Chemomab Therapeutics NASDAQ:CMMB

Liminatus Pharma NASDAQ:LIMN

NLS Pharmaceutics NASDAQ:NCEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LIMN, ALLR, NCEL, and CMMB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LIMN, ALLR, NCEL, and CMMB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LIMN, ALLR, NCEL, and CMMB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LIMN, ALLR, NCEL, and CMMB Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

Chemomab Therapeutics NASDAQ:CMMB

Liminatus Pharma NASDAQ:LIMN

NLS Pharmaceutics NASDAQ:NCEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools